Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07314905 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)

Study acronym: TreatResp
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jan 2, 2026 to Apr 29, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jan 2, 2026 to Apr 29, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.
Trial Details
NCT Number NCT07314905
Lead Sponsor Unity Health Toronto
Collaborators: Canadian Institutes of Health Research (CIHR), Health Canada
Conditions Influenza A, Influenza B, SAR-CoV-2, Acute Respiratory Infections (ARIs)
Enrollment 264 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov